StockNews.com assumed coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research report report published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock. MRTX has been the subject of several other reports. Scotiabank assumed coverage on Mirati Therapeutics in a report on Thursday, July 27th. They […]
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the fourteen analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the […]
JMP Securities restated their market outperform rating on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a report released on Thursday morning, Benzinga reports. JMP Securities currently has a $58.00 target price on the biotechnology company’s stock. Several other equities analysts have also issued reports on MRTX. Morgan Stanley lowered their price target on […]
Mirati Therapeutics (NASDAQ:MRTX – Get Free Report) and BriaCell Therapeutics (OTCMKTS:BCTXF – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk. Volatility & Risk Mirati Therapeutics has a beta […]
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Free Report) EVP Jamie Christensen sold 2,388 shares of the company’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $35.63, for a total value of $85,084.44. Following the sale, the executive vice president now owns 144,032 shares of the company’s […]